Xenon Pharmaceuticals Inc. (XENE)
↓ Download CSV- Sector Manufacturing
- Incorporated A1
- Fiscal year ends Dec 31
In fiscal 2025, Xenon Pharmaceuticals Inc. reported revenue of $7.50M. The company ran a net loss, with a net margin of -4612.1%. It held $633.16M in total assets against $51.40M in total liabilities.
Key ratios (FY2025)
-4974.3%
Operating margin
-4612.1%
Net margin
-59.5%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.50M | $0 | $0 | $9.43M | $18.44M | $32.17M | $6.83M | — | — | — |
| Operating Income | -$373.07M | -$279.30M | -$214.05M | -$129.14M | -$78.99M | -$31.30M | -$42.82M | -$38.04M | -$32.58M | -$24.82M |
| Net Income | -$345.91M | -$234.33M | -$182.39M | -$125.37M | -$78.88M | -$28.84M | -$41.59M | -$34.50M | -$30.70M | -$23.00M |
| EPS (Diluted) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 | $-0.81 | — | $-1.63 | $-1.72 | $-1.48 |
| Total Assets | $633.16M | $798.14M | $964.80M | $754.15M | $572.01M | $189.19M | $147.70M | $122.43M | $46.12M | $67.49M |
| Total Liabilities | $51.40M | $43.24M | $36.88M | $32.65M | $21.97M | $17.83M | $55.72M | $19.13M | $10.19M | $3.59M |
| Shareholders' Equity | $581.76M | $754.90M | $927.92M | $721.50M | $550.03M | $171.35M | $91.98M | $103.30M | $35.93M | $63.90M |
| Cash & Equivalents | $199.16M | $142.71M | $148.64M | $57.24M | $175.69M | $45.01M | $24.75M | $67.75M | $20.49M | $17.09M |
| Operating Cash Flow | -$279.12M | -$181.39M | -$151.11M | -$101.03M | -$69.50M | -$48.12M | -$4.71M | -$34.72M | -$28.73M | — |
| Capital Expenditures | $799.0K | $3.08M | $5.62M | $2.89M | $2.05M | $2.64M | $1.24M | $507.0K | $315.0K | $279.0K |
| Shares Outstanding | 80.01M | 76.42M | 75.37M | 62.59M | 51.63M | 35.01M | 28.14M | 25.75M | 18.00M | 17.93M |